Novo Nordisk A/S（NVO）株価

Novo Nordisk A/S（NVO）はNYSEに上場しているHealthcare · Drug Manufacturers - Generalの企業です。 現在値 $37.54 (+0.59%)、時価総額 $198.26B、PER（株価収益率） 10.38、52週 安値・高値 $35.29 ~ $81.05。

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada

主要指標

• 現在値: $37.54 (+0.59%)
• 時価総額: $198.26B
• PER（株価収益率）: 10.38
• 52週 安値・高値: $35.29 ~ $81.05
• セクター: Healthcare
• 業種: Drug Manufacturers - General
• 取引所: NYSE

Novo Nordisk A/Sの財務諸表、目標株価、機関投資家（13F）の保有状況、関連ニュースは BlackAll Trade でリアルタイムに確認できます。

Novo Nordisk A/S 財務サマリー

アナリスト予想

• アナリスト評価コンセンサス: 3.5

主要財務比率・収益性・成長性

• PBR（株価純資産倍率）: 6.40
• 純利益率: 0.37%
• 営業利益率: 0.62%
• 配当利回り: 0.04%

Novo Nordisk A/S 投資家ディスカッション

最近の投稿 4件・強気 4・弱気 0・中立 0。

• [強気] NVO 임상 좋고 수요 폭발이네, 지금 매수 타이밍임
• [強気] NVO 비만치료제 임상 결과 좋고 수요 폭발 중이라 지금 사도 됨
• [強気] NVO 비만치료제 임상 결과 좋았고 수요 폭발 중이라 지금 사도 됨
• [強気] NVO 비만치료제 임상 결과 좋았고 수요 폭발 중이라 지금 사도 됨

よくある質問